MinervaX ApS, a Danish biotechnology company developing a prophylactic vaccine against Group B Streptococcus (GBS) and Wacker Biotech, a CDMO, entered a collaboration for the manufacture MinervaX’s active protein ingredients of its GBS vaccine.   GBS is responsible for nearly 50 percent of all life-threatening infections in newborns. GBS colonization may lead to late abortions, premature delivery, or stillbirth and in the newborn child, may result in sepsis, pneumonia or meningitis, all ...